Psoriatic arthritis of the hand and nail psoriasis

In this post-hoc study, researchers evaluated the frequency of distal phalangeal involvement in psoriatic arthritis and nail psoriasis. They then compared the efficacy of ixekizumab (anti-IL-17) and adalimumab (anti-TNA-alpha). A total of 354 patients had simultaneous nail and distal interphalangeal joint involvement. Almost all patients with distal interphalangeal joint involvement had nail psoriasis on adjacent nails. With both treatments, complete resolution was significantly higher with ixekizumab than with adalimumab from week 12 of treatment. This effect was maintained up to week 52. Targeting IL-17 would thus be more relevant than targeting TNF-alpha in this context.